Hans-Ulrich Demuth
Plus aucun poste en cours
Profil
Hans-Ulrich Demuth was the founder of Vivoryon Therapeutics NV, which was founded in 1997, where he held the title of Chief Scientific Officer from 2009 to 2013.
He was also a Co-Managing Director at Ingenium Pharmaceuticals GmbH in 2012.
In addition, he was a Principal at Hochschule Anhalt and a Mitglied at Martin-Luther-Universität Halle-Wittenberg.
Dr. Demuth received his undergraduate degree from Martin-Luther-Universität Halle-Wittenberg.
Anciens postes connus de Hans-Ulrich Demuth
| Sociétés | Poste | Fin |
|---|---|---|
| VIVORYON THERAPEUTICS N.V. | Fondateur | 31/01/2013 |
| Hochschule Anhalt | Corporate Officer/Principal | - |
Ingenium Pharmaceuticals GmbH
 Ingenium Pharmaceuticals GmbH Miscellaneous Commercial ServicesCommercial Services Ingenium Pharmaceuticals GmbH operates as a biopharmaceutical company specializing in the development of small molecule drugs. They develop inhibitors and ligands targeting key enzymes such as proteases and kinases. Their therapeutic compounds are used for the treatment of memory-related and chronic inflammatory disorders. Their focus areas cover human therapeutics, vivo pharmacology, and disease pathology. The company was founded in 1998 and is headquartered in Munich, Germany. | Directeur Général | - |
| Martin-Luther-Universität Halle-Wittenberg | Corporate Officer/Principal | - |
Formation de Hans-Ulrich Demuth
| Martin-Luther-Universität Halle-Wittenberg | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| VIVORYON THERAPEUTICS N.V. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Ingenium Pharmaceuticals GmbH
Ingenium Pharmaceuticals GmbH Miscellaneous Commercial ServicesCommercial Services Ingenium Pharmaceuticals GmbH operates as a biopharmaceutical company specializing in the development of small molecule drugs. They develop inhibitors and ligands targeting key enzymes such as proteases and kinases. Their therapeutic compounds are used for the treatment of memory-related and chronic inflammatory disorders. Their focus areas cover human therapeutics, vivo pharmacology, and disease pathology. The company was founded in 1998 and is headquartered in Munich, Germany. | Commercial Services |
